IRADIMED CORP (IRMD) Fundamental Analysis & Valuation
NASDAQ:IRMD • US46266A1097
Current stock price
93.4 USD
-2.16 (-2.26%)
Last:
This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IRMD Profitability Analysis
1.1 Basic Checks
- In the past year IRMD was profitable.
- In the past year IRMD had a positive cash flow from operations.
- Each year in the past 5 years IRMD has been profitable.
- Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
- IRMD has a Return On Assets of 20.67%. This is amongst the best in the industry. IRMD outperforms 98.40% of its industry peers.
- Looking at the Return On Equity, with a value of 23.76%, IRMD belongs to the top of the industry, outperforming 95.74% of the companies in the same industry.
- IRMD's Return On Invested Capital of 21.02% is amongst the best of the industry. IRMD outperforms 98.40% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 9.15%.
- The last Return On Invested Capital (21.02%) for IRMD is above the 3 year average (20.45%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.67% | ||
| ROE | 23.76% | ||
| ROIC | 21.02% |
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
1.3 Margins
- With an excellent Profit Margin value of 26.82%, IRMD belongs to the best of the industry, outperforming 96.81% of the companies in the same industry.
- In the last couple of years the Profit Margin of IRMD has grown nicely.
- Looking at the Operating Margin, with a value of 31.20%, IRMD belongs to the top of the industry, outperforming 98.40% of the companies in the same industry.
- IRMD's Operating Margin has improved in the last couple of years.
- The Gross Margin of IRMD (76.75%) is better than 87.77% of its industry peers.
- IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.2% | ||
| PM (TTM) | 26.82% | ||
| GM | 76.75% |
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
2. IRMD Health Analysis
2.1 Basic Checks
- IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, IRMD has more shares outstanding
- The number of shares outstanding for IRMD has been increased compared to 5 years ago.
- IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- IRMD has an Altman-Z score of 53.76. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 53.76, IRMD belongs to the best of the industry, outperforming 98.94% of the companies in the same industry.
- There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 53.76 |
ROIC/WACC2.35
WACC8.95%
2.3 Liquidity
- A Current Ratio of 7.98 indicates that IRMD has no problem at all paying its short term obligations.
- IRMD has a Current ratio of 7.98. This is amongst the best in the industry. IRMD outperforms 88.30% of its industry peers.
- IRMD has a Quick Ratio of 6.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 6.84, IRMD belongs to the best of the industry, outperforming 88.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.98 | ||
| Quick Ratio | 6.84 |
3. IRMD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 16.36% over the past year.
- IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 36.18% yearly.
- The Revenue has grown by 14.43% in the past year. This is quite good.
- The Revenue has been growing by 21.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
3.2 Future
- The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
- Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 10.59% on average per year.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IRMD Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 48.65, the valuation of IRMD can be described as expensive.
- Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 66.49% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.86. IRMD is valued rather expensively when compared to this.
- A Price/Forward Earnings ratio of 44.02 indicates a quite expensive valuation of IRMD.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 69.15% of the companies listed in the same industry.
- IRMD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 37.39, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.65 | ||
| Fwd PE | 44.02 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 66.49% of the companies in the same industry.
- IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 72.23 | ||
| EV/EBITDA | 41.83 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
- IRMD's earnings are expected to grow with 12.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.63
PEG (5Y)1.34
EPS Next 2Y11.02%
EPS Next 3Y12.36%
5. IRMD Dividend Analysis
5.1 Amount
- IRMD has a yearly dividend return of 0.74%, which is pretty low.
- IRMD's Dividend Yield is rather good when compared to the industry average which is at 0.24. IRMD pays more dividend than 90.96% of the companies in the same industry.
- With a Dividend Yield of 0.74, IRMD pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.74% |
5.2 History
- IRMD has been paying a dividend for over 5 years, so it has already some track record.
- IRMD has decreased its dividend recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 66.90% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP66.9%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
IRMD Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:IRMD (4/10/2026, 8:00:02 PM)
93.4
-2.16 (-2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10 2026-02-10/bmo
Earnings (Next)04-24 2026-04-24
Inst Owners58.92%
Inst Owner Change0%
Ins Owners36.61%
Ins Owner Change-0.61%
Market Cap1.19B
Revenue(TTM)83.81M
Net Income(TTM)22.48M
Analysts82.5
Price Target121.04 (29.59%)
Short Float %6.07%
Short Ratio6.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.74% |
Yearly Dividend1.18
Dividend Growth(5Y)N/A
DP66.9%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-23 2026-02-23 (0.2)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.78%
Min EPS beat(2)1.27%
Max EPS beat(2)10.29%
EPS beat(4)4
Avg EPS beat(4)5.61%
Min EPS beat(4)0.43%
Max EPS beat(4)10.44%
EPS beat(8)7
Avg EPS beat(8)6.02%
EPS beat(12)10
Avg EPS beat(12)6.52%
EPS beat(16)14
Avg EPS beat(16)7.03%
Revenue beat(2)2
Avg Revenue beat(2)2.2%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3%
Revenue beat(4)3
Avg Revenue beat(4)0.84%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)3%
Revenue beat(8)4
Avg Revenue beat(8)0.28%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)7
Avg Revenue beat(16)0.02%
PT rev (1m)-1.11%
PT rev (3m)19.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.65 | ||
| Fwd PE | 44.02 | ||
| P/S | 14.24 | ||
| P/FCF | 72.23 | ||
| P/OCF | 47.85 | ||
| P/B | 12.62 | ||
| P/tB | 13.08 | ||
| EV/EBITDA | 41.83 |
EPS(TTM)1.92
EY2.06%
EPS(NY)2.12
Fwd EY2.27%
FCF(TTM)1.29
FCFY1.38%
OCF(TTM)1.95
OCFY2.09%
SpS6.56
BVpS7.4
TBVpS7.14
PEG (NY)4.63
PEG (5Y)1.34
Graham Number17.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.67% | ||
| ROE | 23.76% | ||
| ROCE | 26.52% | ||
| ROIC | 21.02% | ||
| ROICexc | 43.68% | ||
| ROICexgc | 47.04% | ||
| OM | 31.2% | ||
| PM (TTM) | 26.82% | ||
| GM | 76.75% | ||
| FCFM | 19.72% |
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)54.98%
ROICexgc(5y)60.13%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-13.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 722.21% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.34% | ||
| Profit Quality | 73.51% | ||
| Current Ratio | 7.98 | ||
| Quick Ratio | 6.84 | ||
| Altman-Z | 53.76 |
F-Score6
WACC8.95%
ROIC/WACC2.35
Cap/Depr(3y)948.96%
Cap/Depr(5y)635.99%
Cap/Sales(3y)11.43%
Cap/Sales(5y)7.92%
Profit Quality(3y)64.21%
Profit Quality(5y)73.8%
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.04%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next Year15.66%
EBIT Next 3Y17.6%
EBIT Next 5YN/A
FCF growth 1Y-1.68%
FCF growth 3Y26.52%
FCF growth 5Y26.12%
OCF growth 1Y-2.64%
OCF growth 3Y35.44%
OCF growth 5Y33.79%
IRADIMED CORP / IRMD Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 8 / 10 to IRMD.
Can you provide the valuation status for IRADIMED CORP?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
What is the profitability of IRMD stock?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
What is the earnings growth outlook for IRADIMED CORP?
The Earnings per Share (EPS) of IRADIMED CORP (IRMD) is expected to grow by 10.5% in the next year.
How sustainable is the dividend of IRADIMED CORP (IRMD) stock?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 66.9%.